172 related articles for article (PubMed ID: 3030773)
21. Beneficial actions of thromboxane receptor antagonism in hemorrhagic shock.
Bitterman H; Yanagisawa A; Lefer AM
Circ Shock; 1986; 20(1):1-11. PubMed ID: 2945667
[TBL] [Abstract][Full Text] [Related]
22. Antagonism of thromboxane receptor induced contractions in isolated human groin lymphatics.
Sjöberg T; Andersson KE; Norgren L; Steen S
Lymphology; 1989 Sep; 22(3):135-40. PubMed ID: 2532276
[TBL] [Abstract][Full Text] [Related]
23. Pharmacological profile of BMS 180,291: a potent, long-acting, orally active thromboxane A2/prostaglandin endoperoxide receptor antagonist.
Ogletree ML; Harris DN; Schumacher WA; Webb ML; Misra RN
J Pharmacol Exp Ther; 1993 Feb; 264(2):570-8. PubMed ID: 8437108
[TBL] [Abstract][Full Text] [Related]
24. Effect of endothelin antagonists on the responses to prostanoid endothelium-derived contracting factor.
Moreau P; Takase H; Lüscher TF
Br J Pharmacol; 1996 Jul; 118(6):1429-32. PubMed ID: 8832068
[TBL] [Abstract][Full Text] [Related]
25. Vasorelaxant effect of isoliquiritigenin, a novel soluble guanylate cyclase activator, in rat aorta.
Yu SM; Kuo SC
Br J Pharmacol; 1995 Apr; 114(8):1587-94. PubMed ID: 7599926
[TBL] [Abstract][Full Text] [Related]
26. Antagonism of prostaglandin-mediated responses in platelets and vascular smooth muscle by 13-azaprostanoic acid analogs. Evidence for selective blockade of thromboxane A2 responses.
Huzoor-Akbar ; Mukhopadhyay A; Anderson KS; Navran SS; Romstedt K; Miller DD; Feller DR
Biochem Pharmacol; 1985 Mar; 34(5):641-7. PubMed ID: 3156599
[TBL] [Abstract][Full Text] [Related]
27. The pharmacological profile of the thromboxane A2 antagonist BM 13.177. A new anti-platelet and anti-thrombotic drug.
Stegmeier K; Pill J; Müller-Beckmann B; Schmidt FH; Witte EC; Wolff HP; Patscheke H
Thromb Res; 1984 Aug; 35(4):379-95. PubMed ID: 6385334
[TBL] [Abstract][Full Text] [Related]
28. Daltroban blocks thromboxane responses in the pulmonary vascular bed of the cat.
Hood JS; Nossaman BD; Ibrahim IN; McMahon TJ; Babycos CR; Kadowitz PJ
J Appl Physiol (1985); 1992 Jun; 72(6):2305-10. PubMed ID: 1385804
[TBL] [Abstract][Full Text] [Related]
29. Antiaggregant and antivasospastic properties of the new thromboxane A2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl] methyl]benzeneacetate.
Lardy C; Rousselot C; Chavernac G; Depin JC; Guerrier D
Arzneimittelforschung; 1994 Nov; 44(11):1196-202. PubMed ID: 7848331
[TBL] [Abstract][Full Text] [Related]
30. In vivo attenuation of endothelium-dependent pulmonary vasodilation by methylene blue.
Fineman JR; Crowley MR; Heymann MA; Soifer SJ
J Appl Physiol (1985); 1991 Aug; 71(2):735-41. PubMed ID: 1657862
[TBL] [Abstract][Full Text] [Related]
31. BM 13.505, a selective thromboxane receptor antagonist, reduces myocardial infarct size following coronary artery reperfusion.
Smith EF; Earl CQ; Egan JW
Prostaglandins Leukot Essent Fatty Acids; 1989 Oct; 38(1):15-23. PubMed ID: 2532749
[TBL] [Abstract][Full Text] [Related]
32. Heterogeneity of prostaglandin H2/thromboxane A2 receptors: distinct subtypes mediate vascular smooth muscle contraction and platelet aggregation.
Furci L; Fitzgerald DJ; Fitzgerald GA
J Pharmacol Exp Ther; 1991 Jul; 258(1):74-81. PubMed ID: 1830100
[TBL] [Abstract][Full Text] [Related]
33. Regional differences in the prostanoid receptors mediating prostaglandin F2 alpha-induced contractions of cat isolated arteries.
Nakajima M; Ueda M
Eur J Pharmacol; 1990 Dec; 191(3):359-68. PubMed ID: 2086248
[TBL] [Abstract][Full Text] [Related]
34. Reversal of bradykinin-induced relaxation to contraction after interferon-gamma in bovine isolated mesenteric arteries.
De Kimpe SJ; Tielemans W; Van Heuven-Nolsen D; Nijkamp FP
Eur J Pharmacol; 1994 Aug; 261(1-2):111-20. PubMed ID: 8001633
[TBL] [Abstract][Full Text] [Related]
35. Intrinsic activity of the non-prostanoid thromboxane A2 receptor antagonist, daltroban (BM 13,505), in human platelets in vitro and in the rat vasculature in vivo.
Bertolino F; Valentin JP; Maffre M; Grelac F; Bessac AM; Maclouf J; Delhon A; Lévy-Toledano S; Patoiseau JF; Colpaert FC
Br J Pharmacol; 1995 May; 115(1):210-6. PubMed ID: 7647979
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor.
Yu SM; Wu TS; Teng CM
Br J Pharmacol; 1994 Mar; 111(3):906-12. PubMed ID: 8019768
[TBL] [Abstract][Full Text] [Related]
37. Thromboxane A2 receptor stimulation similarly potentiates pressor responses to 5-hydroxytryptamine in perfused hindquarters of non-diabetic and alloxan diabetic rats.
Sikorski BW; Hodgson WC; King RG
Clin Exp Pharmacol Physiol; 1991 Apr; 18(4):237-44. PubMed ID: 1829992
[TBL] [Abstract][Full Text] [Related]
38. Effect of thromboxane receptor antagonists on venous thrombosis in rats.
Schumacher WA; Heran CL
J Pharmacol Exp Ther; 1989 Mar; 248(3):1109-15. PubMed ID: 2522985
[TBL] [Abstract][Full Text] [Related]
39. Estrogen pretreatment directly potentiates endothelium-dependent vasorelaxation of porcine coronary arteries.
Bell DR; Rensberger HJ; Koritnik DR; Koshy A
Am J Physiol; 1995 Jan; 268(1 Pt 2):H377-83. PubMed ID: 7840287
[TBL] [Abstract][Full Text] [Related]
40. Thromboxane synthetase inhibitors differentially antagonize thromboxane receptors in vascular smooth muscle.
Smith EF; Lefer AM; Smith JB; Nicolaou KC
Naunyn Schmiedebergs Arch Pharmacol; 1981 Dec; 318(2):130-4. PubMed ID: 6276789
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
